Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835540 | 1.00 | NCF1 (0.43) | NCF1HTR7HTR1ADRD2HTR2A | |
| SCHEMBL31579202 | 0.86 | HTR7 (0.43) | NCF1HTR7HTR1ADRD2HTR2A | |
| SCHEMBL21594682 | 0.86 | HTR7 (0.43) | NCF1HTR7HTR1ADRD2HTR2A | |
| SCHEMBL30828396 | 0.82 | HTR7 (0.41) | HTR7HTR1ADRD2HTR2ACLK1 | |
| SCHEMBL19752022 | 0.82 | HTR7 (0.41) | HTR7HTR1ADRD2HTR2ACLK1 | |
| SCHEMBL132925 | 0.82 | HTR7 (0.41) | HTR7HTR1ADRD2HTR2ACLK1 | |
| SCHEMBL4271497 | 0.82 | NCF1 (0.52) | NCF1DYRK1AKDM4EGAAMAPT | |
| SCHEMBL6632726 | 0.79 | HTR7 (0.42) | NCF1HTR7HTR1ADRD2HTR2A | |
| SCHEMBL1110998 | 0.79 | HTR7 (0.42) | HTR7HTR1ADRD2HTR2AGABRA1 | |
| SCHEMBL24323574 | 0.77 | HTR7 (0.41) | HTR7HTR1ADRD2HTR2ACLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122078-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-06-29 | — | — | WO | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| US-20240383894-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | UNIV RUTGERS (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240368181-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4452488-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | Rutgers, The State University Of New Jersey (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023247958-A1 | OXADIAZOLE DERIVATIVES, PREPARATION PROCESS THEREOF AND THEIR USE IN TREATING INFLAMMATORY DISEASES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-28 | — | — | WO | disclosed |
| EP-4288426-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | Black Diamond Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-1595881-A1 | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands | Pfizer Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| EP-1456200-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| US-20040132710-A1 | Lactams as tachkinin antagonists | PFIZER INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2003051868-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
| EP-0984961-B1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| US-6143751-A | Pyridine derivatives and pharmaceutical compositions containing them | ASTRAZENECA UK LIMITED (GB) | 2000-11-07 | — | — | US | disclosed |
| EP-0984961-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Astra Pharmaceuticals Limited (GB) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998043971-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-08 | — | — | WO | disclosed |
| US-4921867-A | Pyridine compounds useful for therapy or prophylaxis of a disease associated with airway obstruction | GLAXO GROUP LIMITED (GB) | 1990-05-01 | — | — | US | disclosed |
| EP-0278728-A2 | 1-(4-Amino-3,5-dichlorophenyl)-2-(substituted amino)ethanol derivatives and their use in the treatment of respiratory disease | GLAXO GROUP LIMITED (GB) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137680-A1 | NOVEL COMPOUNDS | CCR1, CCR4, CCR3 | NCF1 242/4885HTR7 2320/4885HTR1A 1450/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | NCF1 1980/4885HTR7 1929/4885HTR1A 3136/4885 |
| US-20040132710-A1 | Lactams as tachkinin antagonists | PROKR1, TACR2, TACR1 | NCF1 1761/4885HTR7 1598/4885HTR1A 403/4885 |
| US-20240383894-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | NDC1, NUDC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NCF1 109/4885HTR7 542/4885HTR1A 721/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | NCF1 2132/4885HTR7 579/4885HTR1A 1167/4885 |
| US-20240368181-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | NQO2, NQO1, GLS | NCF1 1503/4885HTR7 1218/4885HTR1A 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.